Biotech · Private company
ImmuneSensor Therapeutics Inc.
Track this companyFree. Adds ImmuneSensor Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Immune checkpoint inhibitorPhase 2 · Oligometastatic DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Immune checkpoint inhibitorPhase 2 · OligoprogressiveClinicalTrials.gov · fetched Nov 12, 2026
- Immune checkpoint inhibitor (ICI)Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Immuno-oncology (IO) therapyPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IMSA101Phase 2 · Oligometastatic DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IMSA101Phase 2 · OligoprogressiveClinicalTrials.gov · fetched Nov 12, 2026
- IMSA101Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- PULSARPhase 2 · OligoprogressiveClinicalTrials.gov · fetched Nov 12, 2026
- PULSARPhase 2 · Oligometastatic DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Immune Checkpoint InhibitorPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 TrialPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 15, 2023ClinicalTrials.gov NCT06026254 · fetched Nov 12, 2026
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor MalignanciesPHASE2 · TERMINATED · started Jul 7, 2023ClinicalTrials.gov NCT05846659 · fetched Nov 12, 2026
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCCPHASE2 · TERMINATED · started Jun 28, 2023ClinicalTrials.gov NCT05846646 · fetched Nov 12, 2026
- Safety and Efficacy Study of IMSA101 in Refractory MalignanciesPHASE1_PHASE2 · COMPLETED · started Sep 23, 2019ClinicalTrials.gov NCT04020185 · fetched Nov 12, 2026